lifestyle.celebhomes.net

Author: BioAge Labs, Inc.

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

May 11, 2026
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

May 4, 2026
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

April 21, 2026
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

April 13, 2026
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025

March 24, 2026
BioAge Announces Pricing of Upsized $115.0 Million Public Offering

January 22, 2026
BioAge Announces Proposed Public Offering

January 20, 2026
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

January 20, 2026